Is the incidence and prevalence of inhibitors greater with recombinant products? Yes
Open Access
- 8 April 2004
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (6) , 861-862
- https://doi.org/10.1111/j.1538-7836.2004.00731.x
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Inhibitors in hemophilia patients: Current status and managementAmerican Journal of Hematology, 1994
- Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitateBlood, 1993
- A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study GroupBlood, 1993
- Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of InhibitorsNew England Journal of Medicine, 1993
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcomeBritish Journal of Haematology, 1990